文献速递流行病学与生物统计真实世界研究与卫生经济

真实世界证据可评估乳腺癌化疗有效性:一项队列研究

Real-world evidence was feasible for estimating effectiveness of chemotherapy in breast cancer: a cohort study.
PubMed 文献 · J Clin Epidemiol · 2019-01-31

该研究基于苏格兰癌症登记数据(2001-2015年),纳入39805例女性原发性乳腺癌病例,采用四种因果分析方法评估辅助化疗对疾病特异性死亡和全因死亡的效果,并与随机试验Meta分析比较。结果显示回归调整、倾向评分匹配和工具变量法可行,而回归断点法不可行;乳腺癌死亡率的效果估计与随机试验相似,但全因死亡率不一致。

要点

  • 真实世界证据方法在早期乳腺癌辅助化疗效果评估中可行。
  • 乳腺癌死亡率效果估计与随机试验Meta分析相似。
  • 全因死亡率估计与随机试验不一致,需结合随机证据解读。

核心结论

  • 真实世界证据方法可用于生成早期乳腺癌辅助化疗效果估计。
  • 此类估计需结合现有随机证据及观察性方法潜在偏倚进行解读。

研究设计与样本

  • 研究从苏格兰癌症登记库(SMR06)提取2001至2015年女性原发性乳腺癌病例,并链接常规住院和门诊记录。
  • 共纳入39805例病例进行分析。
  • 采用回归调整、倾向评分匹配、工具变量分析和回归断点设计四种方法估计辅助化疗对疾病特异性死亡和全因死亡的效果。
  • 将乳腺癌死亡和全因死亡的风险比与随机试验Meta分析结果进行比较。

主要发现

  • 回归调整、倾向评分匹配和工具变量法可行,回归断点设计不可行。
  • 乳腺癌死亡率的真实世界证据效果估计与随机试验相似。
  • 全因死亡率的真实世界证据效果估计与随机试验不一致。

临床怎么用

  • 真实世界证据可作为评估辅助化疗效果的可行补充方法。
  • 解读真实世界证据效果估计时需结合随机试验证据和观察性方法偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Evidence-based guidelines recommend adjuvant chemotherapy in early stage breast cancer whenever treatment benefit is considered sufficient to outweigh the associated risks. However, many groups of patients were either excluded from or underrepresented in the clinical trials that form the evidence base for this recommendation. This study aims to determine whether using administrative health care data-real world data-and econometric methods for causal analysis to provide "real world evidence" (RWE) are feasible methods for addressing this gap. METHODS: Cases of primary breast cancer in women from 2001 to 2015 were extracted from the Scottish cancer registry (SMR06) and linked to other routine health records (inpatient and outpatient visits). Four methods were used to estimate the effect of adjuvant chemotherapy on disease-specific and overall mortality: (1) regression with adjustment for covariates, (2) propensity score matching, (3) instrumental variables analysis, and (4) regression discontinuity design. Hazard ratios for breast cancer mortality and all-cause mortality were compared to those from a meta-analysis of randomized trials. RESULTS: A total of 39,805 cases were included in the analyses. Regression adjustment, propensity score matching, and instrumental variables were feasible, whereas regression discontinuity was not. Effectiveness estimates were similar between RWE and randomized trials for breast cancer mortality but not for all-cause mortality. CONCLUSIONS: RWE methods are a feasible means to generate estimates of effectiveness of adjuvant chemotherapy in early stage breast cancer. However, such estimates must be interpreted in the context of the available randomized evidence and the potential biases of the observational methods.

来源:J Clin Epidemiol,查看原文。版权归原作者所有。

引用

  1. Gray E, Marti J, Brewster DH, et al. Real-world evidence was feasible for estimating effectiveness of chemotherapy in breast cancer: a cohort study. J Clin Epidemiol. 2019. PMID: 30711490. doi:10.1016/j.jclinepi.2019.01.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。